Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.
Dupilumab significantly reduces exacerbations and improves lung function in COPD patients with elevated eosinophil counts, confirming the efficacy of targeting type 2 inflammation.